Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Fibrobiologics Inc. (FBLG:NASDAQ), powered by AI.
Fibrobiologics Inc. is currently trading at $0.81. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Fibrobiologics Inc. on Alpha Lenz.
Fibrobiologics Inc.'s P/E ratio is -0.1.
“Fibrobiologics Inc. trades at a P/E of -0.1 (undervalued) with modest ROE of -419.4%.”
Ask for details →Fibrobiologics Inc. is a cutting-edge biotechnology company involved in the field of regenerative medicine. This company's primary focus is on the development of fibroblast-based technologies and therapies aimed at repairing and regenerating damaged tissues. Fibrobiologics uses fibroblast cells, which are critical for tissue maintenance and wound healing, to create innovative treatments for a variety of conditions, including chronic wounds, degenerative diseases, and age-related conditions. The firm heavily engages in research and development, working to harness the natural capabilities of fibroblasts in addressing unmet medical needs. The role of Fibrobiologics Inc. in the financial market is significant due to its potential impact on the healthcare sector, as advancements in regenerative medicine could lead to major breakthroughs in patient care and treatment efficacy. Within the broader biotechnology industry, Fibrobiologics plays a crucial role, contributing to the ongoing evolution of next-generation therapies that are likely to enhance the quality of life for many patients.
“Fibrobiologics Inc. trades at a P/E of -0.1 (undervalued) with modest ROE of -419.4%.”
Ask for details →Fibrobiologics Inc. (ticker: FBLG) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 13 employees. Market cap is $2M.
The current price is $0.81 with a P/E ratio of -0.1x and P/B of 0.29x.
ROE is -419.44%.